[go: up one dir, main page]

AU6773598A - Treatment of gastrointestinal disease with ppar modulators - Google Patents

Treatment of gastrointestinal disease with ppar modulators

Info

Publication number
AU6773598A
AU6773598A AU67735/98A AU6773598A AU6773598A AU 6773598 A AU6773598 A AU 6773598A AU 67735/98 A AU67735/98 A AU 67735/98A AU 6773598 A AU6773598 A AU 6773598A AU 6773598 A AU6773598 A AU 6773598A
Authority
AU
Australia
Prior art keywords
treatment
gastrointestinal disease
ppar modulators
ppar
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67735/98A
Inventor
Johan Auwerx
Michael R Briggs
Anne-Marie Lefebvre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Ligand Pharmaceuticals Inc
Original Assignee
Institut Pasteur
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur, Ligand Pharmaceuticals Inc filed Critical Institut Pasteur
Publication of AU6773598A publication Critical patent/AU6773598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU67735/98A 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators Abandoned AU6773598A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4137297P 1997-03-26 1997-03-26
US60041372 1997-03-26
PCT/US1998/005852 WO1998043081A1 (en) 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators

Publications (1)

Publication Number Publication Date
AU6773598A true AU6773598A (en) 1998-10-20

Family

ID=21916159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67735/98A Abandoned AU6773598A (en) 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators

Country Status (2)

Country Link
AU (1) AU6773598A (en)
WO (1) WO1998043081A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
AU2943300A (en) * 1999-03-11 2000-09-28 Institute Of Research And Innovation Novel ligands of nuclear receptors ppar's
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
US6159734A (en) * 2000-01-18 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of peroxisome proliferator-activated receptor gamma expression
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (en) 2001-01-26 2010-12-31 Schering Corporation Combination of receptor activator activated by fenofibrate peroxisome-proliferator (ppar) with sterol absorption inhibitor ezetimibe for vascular indications
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
HU230435B1 (en) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Use of substituted azetidinone compounds for treatment of sitosterolemia
WO2002070011A2 (en) * 2001-02-02 2002-09-12 Smithkline Beecham Corporation Treatment of ppar mediated diseases
JPWO2002080899A1 (en) * 2001-03-30 2005-01-06 エーザイ株式会社 Gastrointestinal disease treatment
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
GB0127916D0 (en) * 2001-11-21 2002-01-16 Rowett Res Inst Method
MXPA05004811A (en) 2002-11-06 2005-07-22 Schering Corp Cholesterol absorptions inhibitors for the treatment of autoimmune disorders.
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (en) 2003-03-07 2005-10-18 Schering Corp Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia.
MXPA05009502A (en) 2003-03-07 2005-10-18 Schering Corp Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20080286260A1 (en) * 2004-03-26 2008-11-20 Bayer Healthcare Ag Diagnostic and Therapeutics for Diseases Associated with Peroxisome Proliferative Activated Receptor Alpha (Ppara)
ITMI20041825A1 (en) * 2004-09-24 2004-12-24 Medestea Res & Production Srl RECEPTOR AGONISTS ACTIVATING THE PROLIFERATION OF PEROXYSOMES, USEFUL IN THE PREVENTION OR TREATMENT OF GASTRITIS
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
ITRM20050390A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
AU2007266714B2 (en) 2006-01-18 2013-03-14 Evolva Sa PPAR modulators
BRPI0806686A2 (en) 2007-01-18 2014-11-04 Evolva Sa COMPOUNDS AND ITS USES, METHODS OF TREATMENT OR PREVENTION, PHARMACEUTICAL COMPOSITIONS AND CRYSTALLINE COMPOUND AND SOLVAT
JP5662682B2 (en) 2007-01-18 2015-02-04 エヴォルヴァ エスアー Substituted 1,3-dioxanes useful as PPAR modulators
WO2008104305A1 (en) * 2007-02-27 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Pygm as a biomarker for ppara modulators
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
PT2396081T (en) 2009-02-16 2017-07-11 Nogra Pharma Ltd Alkylamido compounds and uses thereof
JP5180978B2 (en) * 2010-02-01 2013-04-10 花王株式会社 Screening method for anti-obesity substances
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP2811993B1 (en) 2012-02-09 2019-10-09 Nogra Pharma Limited Methods of treating fibrosis
IN2014DN08157A (en) 2012-04-18 2015-05-01 Nogra Pharma Ltd
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
KR102523805B1 (en) 2014-12-23 2023-04-20 4디 파마 리서치 리미티드 Immune modulation
KR20170091157A (en) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 Pirin polypeptide and immune modulation
PL3240554T3 (en) 2015-06-15 2020-02-28 4D Pharma Research Limited Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
RS59038B1 (en) 2015-06-15 2019-08-30 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6426264B2 (en) 2015-06-15 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ Compositions comprising bacterial strains
CA3005781C (en) 2015-11-20 2019-01-22 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
HK1246670B (en) 2016-03-04 2020-05-15 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (en) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 Composition comprising a bacterial strain
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3630136B1 (en) 2017-05-22 2021-04-21 4D Pharma Research Limited Compositions comprising bacterial strains
MA41708A (en) 2017-05-24 2020-04-08 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
EP3600363B1 (en) 2017-06-14 2020-12-02 4D Pharma Research Limited Compositions comprising bacterial strains
HUE052258T2 (en) 2017-06-14 2021-04-28 4D Pharma Res Ltd A composition comprising a bacterial strain belonging to the genus Megasphaera and its use
SI3921299T1 (en) 2019-02-08 2025-03-31 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
CN112168820B (en) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 Application of SRCAP ATPase inhibitor in colorectal cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2269897A (en) * 1992-08-13 1994-02-23 Merck Frosst Canada Inc Assay to detect peroxisome proliferator activity

Also Published As

Publication number Publication date
WO1998043081A1 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
AU6773598A (en) Treatment of gastrointestinal disease with ppar modulators
AU4050797A (en) Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU5872696A (en) Endoscope
AU7268298A (en) Differential treatment of prosthetic devices
AU3075895A (en) Endoscope
AU1450900A (en) Methods of treatment of type 2 diabetes
AU7592998A (en) Modulators of tissue regeneration
AU5899798A (en) Aminoacyl sulfamides for the treatment of hyperproliferative disorders
AU6928098A (en) Optical modulator
AU3596199A (en) Treatment of celiac disease
AU3322795A (en) Endoscope
AU1184399A (en) Therapeutic molecules
AU2105897A (en) Organic photoconductor and treatment therefor
AU1645599A (en) Human matrilin-3
AU696976B2 (en) Effluent treatment
AU8557598A (en) Treatment of fluids
AU4124497A (en) Treatment of diabetes
AUPO948197A0 (en) Diagnosis of parasites
AUPO632997A0 (en) Diagnosis of parasites
AUPO495397A0 (en) Diagnosis of parasites
AU2002302012A1 (en) Chromim/biotin treatment of type II diabetes
AUPO364796A0 (en) Diagnosis of parasites II
AU698264B3 (en) Water treatment
AU2002301764A1 (en) Treatment with anti-Erb2 antibodies
AUPO359496A0 (en) Diagnosis of parasites